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doi:10.1Objective: This study sought to evaluate the performance of microaxial ventricular assist devices for the pur-
poses of supporting failing Fontan physiology by decreasing central venous pressure.
Methods: Three Abiomed Impella pumps (Abiomed, Inc, Danvers, Mass) were evaluated in a mock circulatory
system of the Fontan circuit. The local response of pressures and flows to pump function was assessed as a func-
tion of pump speed and pulmonary vascular resistance at a high baseline central venous pressure. For one device,
subsequent modeling studies were conducted using a lumped parameter model of the single ventricle circuit.
Results: The left ventricular devices (Impella 2.5, 5.0) were shown to be suboptimal as single device solutions
for cavopulmonary support. The small area of these devices relative to vessel diameter led to significant flow
recirculation without an obstructive separator in place. Furthermore, downstream pressure augmentation ad-
versely affected the pressure in the superior vena cava. The use of 2 devices would be mandatory for successful
support. The right-sided device (Impella RP), whose outflow was positioned in the left pulmonary artery, dem-
onstrated decreased flow recirculation and did not impede superior caval venous flow. Although static pressure is
still required to drive flow through the opposite lung, numeric modeling demonstrated the potential for modest
but significant improvements in lowering the central venous pressure (2–8 mm Hg).
Conclusions: Left-sided microaxial pumps are not well suited for cavopulmonary support because of severe
flow recirculation and the need for multiple devices. The right-ventricular Impella device provides improved
performance by directing flow into the pulmonary artery, resulting in modest decreases in central venous pres-
sure. (J Thorac Cardiovasc Surg 2012;144:563-9)Without the function of a subpulmonary pump, patients
with a single functional ventricle are subjected to drastically
altered hemodynamics compared with the normal circula-
tion. Staged surgical palliation to achieve a right heart
bypass (the Fontan procedure1) is the most common treat-
ment strategy, resulting in a total cavopulmonary connec-
tion (TCPC). The TCPC requires that the pulmonary
blood flow is passively driven by intrathoracic, cardiopha-
sic, and static venous forces.2 Chronic exposure to these
conditions results in gradual attrition and the development
of numerous life-threatening sequelae,3 including abnor-
malities related to altered hepatic and gastrointestinal func-
tion or perfusion, such as protein-losing enteropathy, liver
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The Journal of Thoracic and CaThe concept of mechanical compensation for the missing
ventricle of the Fontan circulation is a popular hypothesis
for improving these hemodynamics.6-12 The basic idea of
such an approach is to deploy the cavopulmonary assist
device inside or parallel to the TCPC to simultaneously
reduce the systemic venous pressure head while augmenting
pulmonary pressures and flows. Because of the unique
hemodynamic requirements of this operating environment
compared with those of the left ventricle (for which most
existing mechanical blood pumps are designed), most
advocates have proposed novel device designs for this
application.6,10,12 Although such devices have the potential
for long-term benefit, the significant time required for devel-
opment, testing, and regulatory review impairs their ability to
fulfill the immediate need for such therapies.
Alternatively, this study investigates the possibilities for
using existing ventricular assist devices for cavopulmonary
assistance, particularly focusing on a number of different
percutaneous axial flow Impella devices developed by
Abiomed, Inc (Danvers, Mass). By using a combination
of experimental and numeric models of failing Fontan cir-
culation (ie, having high central venous pressures
[CVPs]), the specific objective was to characterize the local
response of pressures and flows at the level of the TCPC to
assess the viability of the specific devices for the cavopul-
monary application.rdiovascular Surgery c Volume 144, Number 3 563
Abbreviations and Acronyms
CVP ¼ central venous pressure
IVC ¼ inferior vena cava
LPA ¼ left pulmonary artery
PA ¼ pulmonary artery
PVR ¼ pulmonary vascular resistance
RPA ¼ right pulmonary artery
RPM ¼ revolutions per minute
SVC ¼ superior vena cava
TCPC ¼ total cavopulmonary connection
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Experimental Setup
A mock circulatory loop of the cavopulmonary connection was con-
structed to experimentally evaluate pump performance (Figure 1, A). Sep-
arate steady, submersible pumps were used to continuously fill the superior
and inferior central venous reservoirs to the desired pressure level. The
system was noncompliant in that a fixed circulating fluid volume was not
enforced. A rapid-prototyped replica of a patient-specific lateral tunnel
TCPC from a 19-year-old Fontan case was used as the experimental model
(Figure 1, B). An atrial overflow reservoir was placed downstream of the
pulmonary arterial branches to fix the atrial pressure at 12.5 mm Hg.
Adjustable clamps were also placed downstream of the TCPC to set the
pulmonary vascular resistance (PVR). Flow rates were measured using
Transonic flow probes (Transonic Inc, Ithaca, NY) in the inferior vena
cava (IVC), left pulmonary artery (LPA) and right pulmonary artery
(RPA). The superior vena cava (SVC) flow rate was estimated as the differ-
ence between the branch pulmonary artery (PA) and IVC rates. Pressure
ports were placed at uniform distances from the connection to measure
static fluid pressure via vertical water column height.
Investigated Devices
Three Abiomed microaxial pumps were tested: 2 left ventricular assist
devices of varying size motors (Impella 5.0 and Impella 2.5) and a right
ventricular device (Impella RP) (Figure 1, C). The LV devices were de-
ployed via insertion through the SVC (simulating a cutdown of the jugular
vein) and passed into the TCPC such that the inlet was positioned in the
IVC and the motor and outlet were immediately inferior to the IVC-PA
junction (Figure 1, D). On the basis of concerns of flow recirculation about
the body of the device, experiments with the 5.0 were conducted both with
and without an occlusive plug in place to separate the inlet and outlet. The
RP device, which has the same motor as the 5.0 but reversed to direct flow
to the distal end, was alternatively inserted through the IVC (simulating
femoral venous access) and directed into the branch LPA (Figure 1, E).
Experimental Conditions
Experiments were conducted at a CVP of 20 mm Hg to approximate
chronically elevated Fontan pressures at a level that may warrant clinical
consideration for mechanical support. Pulmonary pressures and flows
were subsequently varied by imposing alternate PVR levels of 0.5, 1.5,
and 3.0 mm Hg $ min/L (taking the difference between proximal pulmo-
nary and atrial pressures as the transpulmonary gradient). Baseline hemo-
dynamics for these various conditions were established before pump
deployment, and results reported as ‘‘D’’ thus represent the change from
these baseline conditions.
The acute responses (with respect to cavopulmonary pressures and
flows) to pump function were then characterized as a function of pump
speed and PVR once the devices were inserted. The exact rotational speeds564 The Journal of Thoracic and Cardiovascular Surgvaried by motor size, but corresponded to the P2, P5, and P9 settings in the
pump controller. For the 2.5 model, these speeds were 35,000, 43,000, and
51,000 revolutions per minute (RPM), whereas the 5.0 and RP speeds were
17,000, 24,000, and 33,000 RPM.
Finally, the RP model was tested at the additional CVP condition of 25
mm Hg and finer PVR spacing (0.5–3.0 mm Hg $ min/L in increments of
0.5). Baseline measurements were again acquired at these conditions and
compared with results with the pump deployed.
Lumped Parameter Modeling
To complement the experimental investigations, which did not account
for ventricular or systemic arterial responses to pump function, lumped pa-
rameter modeling, using the model described by Pekkan and colleagues,11
was also performed. Details on the structure and formulation for this spe-
cific model have been described by Sundareswaran and colleagues.13 The
existing circuit was modified to allow explicit representation of the RP de-
vice according to the experimental design (ie, IVC-to-LPA placement), and
the model variables governing pump function (Au and Rpump; pump inertial
constant and internal resistance, respectively) were selected on the basis of
the experimental data. All model parameters are provided in Table 1.RESULTS
Left Ventricular Devices
The experimental results from the Impella 2.5 device
(with no occlusive plug in place) as a function of pump
speed and PVR are shown in Table 2. A built-in sensor
was used to measure flow through the pump at each condi-
tion (Qpump), which reached a maximum of 2.3 L/min (com-
pared with the designed maximum of 2.5) at the highest
RPM setting, and showed little sensitivity to changes in
PVR. The changes in IVC flow from baseline, as well as
the changes in total pulmonary flow, were less than the re-
ported pump flow in each case, denoting significant recircu-
lation about the device. Further, the recirculation increased
with increasing PVR; the total pulmonary flow was less
at the 3.0 mm Hg $ min/L condition than at 1.5 mm
Hg $ min/L. Pressure in the IVC reduced by as much as
2.3mmHg in the short duration of the experiment; however,
SVC pressures increased to levels at or above the PAs in
each case.
Table 2 also compares the results of the Impella 5.0 with
and without an occlusive plug at 1.5 mmHg $min/L PVR. It
is noted that no sensor was available on the 5.0 device to
measure pump flow. Without the plug, the results mirrored
those of the 2.5 device: minimal improvements in pulmo-
nary forward flow and modest decreases in IVC pressure
with increases in downstream (SVC and PA) pressures.
An asymmetric response with respect to the PA pressures
and flows was seen in this case (ie, RPA pressure and flow
decreased), which was most likely related to the exact
placement and orientation of the pump outlet inside the
large lateral tunnel connection.
Once the plug was inserted (removing the potential for
flow recirculation around the device), the increase in down-
stream pressures was accentuated and occurred rapidly with
the onset of pump function. Subsequent increases inery c September 2012
FIGURE 1. Details of experimental setup. A, Schematic of mock circulatory loop. B, Anterior and superior views of computer-aided design model for
patient-specific TCPC used in experimental setup. C, The 3 microaxial devices used in the study are 2.5, 5.0, and RP (left to right). Arrows denote position
of the motor and direction of flow. D, Positioning of deployed 5.0 device with respect to TCPCmodel. E, Positioning of the RP device with respect to TCPC
model. LA, Left atrium; SV, superior vein; IV, inferior vein; PVR, pulmonary vascular resistance; TCPC, total cavopulmonary connection; RPA, right pul-
monary artery; SVC, superior vena cava; LPA, left pulmonary artery; IVC, inferior vena cava.
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the SVC contribution to pulmonary flow decreased with in-
creasing pump speed.
Impella RP
As seen in Figure 2, A and B, placement of the RP pump
in the branch LPA augmented LPA pressure, particularly
with increasing pump speed and PVR. The pressure in-
crease was particularly pronounced at the higher baseline
CVP, reaching a maximum of approximately 60 mm Hg
at peak RPM and 3 mm Hg $ min/L PVR. The device
also increased LPA flow (Figure 2, C) by up to 1.5 L/min,
decreasing with higher downstream resistance. As with
the left ventricular devices, flow recirculation was still pres-
ent (assessed by subtracting the device flow via the on-
board sensor from the measured LPA flow) and increased
with higher pump speeds and downstream resistances.
With respect to the hemodynamics in the rest of the connec-
tion (Table 2), there were minimal acute changes in IVC andThe Journal of Thoracic and CaSVC pressure, and small increases in flow. Minor decreases
in RPA pressure and flow were noted.
Lumped Parameter Modeling
Figure 3, A–C, shows the predicted physiologic response
to RP deployment as a function of pump speed at constant
resistance and compliance values (ie, with no allowance
for physiologic adaptation or response). Cardiac output pro-
gressively improved by virtue of increased ventricular pre-
load (ie, improved diastolic filling; Figure 3, A), which led
to subsequent increases in caval flow rates (Figure 3, B).
RPA flow decreased slightly with increasing pump speed.
With respect to TCPC pressure changes (Figure 3, C), the
LPA increased significantly (16 mmHg) with higher rota-
tional speeds, whereas the other vessels all decreased
slightly (IVC 2 mm Hg).
Figure 3, D, shows the response of TCPC pressures for
a series of different LPA resistances at a constant pump
speed. Decreased pressures were observed in each case,rdiovascular Surgery c Volume 144, Number 3 565
TABLE 1. Summary of values prescribed in the lumped parameter
model
Parameter Lumped parameter value
CSV Max, mL/mm Hg 330 (total)
CSA, mL/mm Hg 0.5
RSSV, mm Hg $ min/L 45
RISV, mm Hg 40
CPV, mL/mm Hg 80 (total)
CPA, mL/mm Hg 4.12
RRPV, mm Hg $ min/L 7
RLPV, mm Hg $ min/L 8
RTCPC, mm Hg $ min/L 3.0
RMV/AV, mm Hg $ min/L 0.01
CV(min), L/mm Hg 0.03
CV(max), mL/mm Hg 12.5
Au (mm Hg/RPM
2) 1.7e-8
Rpump (mm Hg $ min/L) 0.06
C, Compliance; CPC, cavopulmonary connection;MV,mitral valve; AV, aortic valve;
PA, pulmonary artery; PV, pulmonary vein; R, resistance; SA, systemic artery; SSV,
superior systemic vein; ISV, inferior systemic veins; V, single ventricle; AV, aortic
valve; RPV, right pulmonary vein; LPV, left pulmonary vein; Au, Rpump, pump
constants.
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pressure.
Finally, to characterize the response to hypothetic vascu-
lar compliance remodeling, the maximum inferior systemic
venous compliance was increased (0.1 to 0.2 L/mm Hg,
bringing total compliance from 0.3 to 0.4). The LPA resis-
tance was set in the middle range of the previous simulation
set (4 mm Hg $min/L), and the pump speed was kept in the
middle range (24k RPM). Figure 3, E, shows the subsequent
decreases in cardiac output (16%), RPA flow (26%), and
IVC pressure (22%; 3.5 mm Hg).TABLE 2. Experimental results
RPM Qpump DQIVC DQSVC
2.5 pump (1.5 mm Hg $ min/L) 35k 1.5 0.3 0.1
43k 1.9 0.4 0.1
51k 2.2 0.6 0.1
2.5 pump (3.0 mm Hg $ min/L) 35k 1.5 0.1 0.1
43k 1.9 0.1 0.0
51k 2.3 0.2 0.1
5.0 pump* No plug 17k 0.5 0.5
24k 0.3 0.1
33k 0.3 0.1
QIVC
5.0 pump* With plug 17k 1.8 0.1
24k 2.7 0.5
33k 3.7 1.0
RP pump* 20 mm Hg CVP 17k 1 0.2 0.0
24k 2.5 0.3 0.2
33k 4.1 0.6 0.5
RP pump* 25 mm Hg CVP 17k 1.2 0.2 0.0
24k 2.6 0.3 0.0
33k 4.1 0.5 0.3
N/A, Not applicable; Qpump, flow value reported by pump sensor; D, difference from base
566 The Journal of Thoracic and Cardiovascular SurgDISCUSSION
The concept of using an axial flow pump in the IVC to
augment cavopulmonary hemodynamics has been
explored.6,7,9,12 The potential use and implications of
the left ventricular Impella pump designs for this
application have been discussed12,14,15 but never
explicitly examined. The limitations most commonly
cited include the need for a recirculation barrier, such as
an expandable balloon (which may be a severe hazard in
the case of device failure); the substantial operational
speeds and pressure generation inherent to a left-sided de-
vice; and the potential collapse of upstream vasculature be-
cause of high inlet suction. Given the allure of the Impella
devices for cavopulmonary application (because of their
small size and ability to deploy percutaneously), conclu-
sively testing these hypotheses is a valuable contribution
of this work.
The findings of this study largely support the hypothe-
sized outcomes, although it is notable that excessive
pressure generation was not observed. The strongest agree-
ment was that without an occlusive barrier, minimal aug-
mentation of forward flow was observed, signaling
significant recirculation about the pump. This configuration
is both ineffective and potentially harmful to blood ele-
ments through continued exposure to high fluid shear stress.
However, with the barrier in place, the immediate limitation
(more than the potential for pump failure) was the need for
a second (SVC-deployed) device8 because of the substantial
increase in SVC pressures that accompanied IVC augmen-
tation. Given the traditional shape of the TCPC (opposing
SVC and IVC orientations), this effect is unavoidable for
a single axial device because any augmentation ofDQLPA DQRPA DPIVC DPSVC DPLPA DPRPA
0.1 0.1 1.1 0.5 0.5 0.3
0.2 0.1 1.7 0.9 0.9 0.7
0.3 0.2 2.2 1.5 1.2 1.1
0.0 0.0 1.1 0.4 0.5 0.5
0.1 0.1 1.3 1.2 1.3 1.1
0.1 0.1 2.0 1.9 1.8 1.6
0.2 0.1 0.7 0.5 0.9 0.5
0.3 0.1 1.4 1.1 1.9 0.6
0.6 0.2 2.6 2.1 3.9 0.6
1.2 0.5 N/A 4.1 3.4 3.5
1.5 1.0 N/A 8.0 6.4 5.6
1.7 1.4 N/A 11.5 8.8 7.8
0.2 0.1 0.0 0.0 3.4 0.0
0.6 0.1 0.0 0.0 8.2 0.0
1.2 0.1 0.3 0.3 10.8 0.5
0.3 0.0 0.0 0.0 4.8 0.1
0.6 0.2 0.0 0.0 12.0 0.1
1.1 0.0 0.1 0.0 16.3 0.2
line value. *PVR ¼ 1.5.
ery c September 2012
FIGURE 2. Detailed experimental results for the RP device showing the responses of (A, B) LPA pressure (at different baseline CVP values), LPA flow (C),
and flow recirculation (D) as functions of pump speed (horizontal axes) and PVR (column colors). LPA,Left pulmonary artery;CVP, central venous pressure;
PVR, pulmonary vascular resistance; PLPA, left pulmonary artery pressure; QLPA, left pulmonary artery flow.
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the SVC.
The implications of SVC hypertension in this setting are
debatable. On the one hand, the use of ‘‘one-and-a-half ven-
tricle’’ repair to palliate certain complex congenital heart
defects suggests that the SVC pressure can safely be ele-
vated to near normal levels of pulmonary arterial pres-
sure.16,17 However, there is phasic variability to those
pressure waves—a short duration of elevated systemic
pressure, followed by a significant duration of lower mean
pressure. That is a critical distinction from the constant
high pressure state that would be imposed by axial flow
support, because venous compliance could no longer act as
a shield against phasic variability to protect the upstream
organs. Furthermore, patients targeted for cavopulmonary
assist interventions may have a combination of factors
resulting in Fontan failure, including issues with venous
capacitance and compliance, vascular permeability, and
pleural effusions, which could be compounded in an SVC
hypertensive state.18,19 This physiology may also result in
hypertension in the subclavian veins and the thoracic duct,
which could therefore lead to problems with fluid
homeostasis and the clearance of pleural fluids.20 For these
reasons, we concur with the assertions of Rodefeld and col-
leagues8 that simultaneous support of both the IVC and
SVC is important for axial device approaches. However, the
invasiveness of insertingmultiple devicesmay be prohibitive,
particularly for smaller patients, and the obstructive flow
barrier concerns remain.The Journal of Thoracic and CaImpella RP
The evaluation of a new right-sided Impella device in the
cavopulmonary setting is novel. The experimental results
demonstrated that augmentation of pressure and flow to
the deployed lung were achieved, with no observed adverse
effects on superior caval hemodynamics. The accompany-
ing lumped parameter modeling showed that reductions in
CVP were possible. The absolute magnitudes of these de-
creases will be dependent on the specific response of the
patient-specific physiology to pump function; however,
these results suggest possible CVP changes on par with
levels previously suggested to have a beneficial effect for
reversing the Fontan paradox.11
Recognizing the inherent dependence of the quantitative
findings of the lumped parameter modeling on the
assumptions made, a brief justification is warranted. The
expected response to increased LPA flow is a decrease in
local vascular resistance (eg, vessel dilation) to maintain
homeostatic levels of wall shear stress.21 Without knowl-
edge of the exact magnitude of the response, the parametric
evaluation of LPA resistance values was warranted. As ex-
pected, the local flow increased with decreasing levels of
pressure generation. The second assumption made was the
compliance remodeling. It is well established that patients
undergoing the Fontan have severely decreased systemic
venous compliance.18 This altered physiology results in el-
evated venous pressures, which are needed to passively
drive pulmonary flow; therefore, some compliance recovery
could relieve the hypertension. However, the conditions orrdiovascular Surgery c Volume 144, Number 3 567
FIGURE 3. Summary of lumped parameter modeling for RP configuration in TCPC. A, Ventricular pressure-volume relationships with increasing pump
speed. Changes in vessel (B) flow rates and (C) pressures as a function of pump speed with all other parameters unchanged. D, Pressure response for each
TCPC vessel as a function of decreasing LPA resistance (R, in mm Hg $ min/L). E, Changes in cardiac output, RPA flow, and IVC pressure in response to
increased systemic venous compliance. RPA, Right pulmonary artery; IVC, inferior vena cava; SV, single ventricle; SVC, superior vena cava; LPA, left pul-
monary artery; AO, aorta; RPM, revolutions per minute.
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known; any animal modeling done in this space uses acute
models that do not undergo such remodeling. The
approximation of remodeling was therefore arbitrary, yet
conservative compared with ‘‘healthy’’ compliance values
(0.4 vs 1.5 L/mm Hg).13 The response to this small change
was significant, suggesting that for patients capable of such
vascular adaptation, this intervention could provide a hemo-
dynamic benefit in lieu of therapeutic alternatives.
Despite the demonstrated potential of the RP device as
a cavopulmonary assist device in this pilot investigation,
several observed limitations of this device are noted in an-
ticipation of further study and testing. The decrease in
CVP predicted was limited for the primary reason that
a static pressure head was still required to passively drive
flow through the contralateral lung. The addition of a pulmo-
nary vasodilator, such as nitric oxide or sildenafil, might im-
prove device effectiveness by lowering PVR and decreasing
the venous pressure needed to drive RPA flow.22 There is
still potential for flow recirculation, although the consider-
able length of this pump could provide the advantage of
extreme distal placement of the pump outlet to further568 The Journal of Thoracic and Cardiovascular Surgpromote forward flow. Finally, the size of the RP may be
limiting for minimally invasive deployment, particularly
in smaller or younger patients. The predicted success of uni-
lateral lung perfusion could be similarly recreated using
other devices, such as external centrifugal pumps with ap-
propriately sized cannulae, in patients in whom size con-
straints are a concern.
Limitations
There are several limitations to this preliminary study
that preclude a more conclusive statement regarding the
success of these therapeutic options. First, stiff tubing was
primarily used for the experimental setup such that vessel
collapse (from pump suction), which has been previously
noted in left-sided devices in this low-pressure setting,
could not be assessed. Second, the mock circulatory setup
used was simplified and did not incorporate ventricular or
systemic arterial responses, as other similar studies have.
It was for this reason that lumped parameter modeling
was used for the RP device. Explicit experimental represen-
tation of these components would require the same assump-
tions used by the lumped parameter model. Finally, theery c September 2012
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driven, as opposed to the parameters being dynamically
adaptive. Because the actual response is unknown and po-
tentially patient-specific, we cannot claim that the results
are exactly representative of what the response of an indi-
vidual patient will be. Instead, these data serve 3 purposes:
(1) demonstrate the potential hemodynamic benefits of cav-
opulmonary assistancewith an Impella RP, (2) reveal poten-
tial roadblocks to a successful intervention with an RP-style
configuration, and (3) identify the critical variable factors
on which future investigations studies should focus in as-
sessing device effectiveness.
CONCLUSIONS
Three different microaxial, intravascular ventricular as-
sist devices were experimentally evaluated in the context
of supporting a patient with a failing Fontan in the hopes
of temporarily reversing the Fontan paradox. The left ven-
tricular Impella devices were shown to have severe short-
comings with respect to flow recirculation (and the need
for physical separation between the pump inlet and the out-
let) and the need for 2 devices (to avoid venous hyperten-
sion in the superior systemic circuit). The new right
ventricular Impella RP device was experimentally and nu-
merically shown to circumvent some of these shortcomings
by laterally directing flow to one branch PA and theoreti-
cally achieving moderate decreases in CVP. Although not
an ideal solution because of the need for passive flow to
the contralateral lung, this device may have the potential
to provide targeted benefit to patients with a failed Fontan
without other therapeutic alternatives.
Dr Scott Corbett and Abiomed, Inc, provided the devices for the
analysis. This study was supported by the Food and Drug Admin-
istration through the Pediatric Device Consortium Program and the
specific efforts of the Pediatric Cardiovascular Device Consortium
(FD003792; PI, Dr del Nido).
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